Enveloped Virus-like Particle Delivery of an Optimized Form of CMV gB Antigen for Prophylactic Vaccination Against Congenital CMV

10th Vaccine Congress
Amsterdam, Netherlands

September 5th, 2016
Francisco Diaz-Mitoma
Chief Medical Officer
Cautionary Statement Regarding Forward-Looking Information

Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “goals” and similar expressions. All statements other than statements of historical fact included in this presentation are forward-looking statements.

Such forward-looking statements are based on a number of assumptions, including, without limitation, assumptions regarding the successful development and/or commercialization of the company’s products, such as the receipt of necessary regulatory approvals; general economic conditions; that the company’s business is able to operate as anticipated without interruptions; competitive conditions; and changes in applicable laws, rules and regulations.

Although management believes that the assumptions made and expectations represented by such statements are reasonable, there can be no assurance that a forward-looking statement contained herein will prove to be accurate. Actual results and developments may differ materially from those expressed or implied by the forward-looking statements contained herein, and, even if such actual results and developments are realized or substantially realized, there can be no assurance that they will have the expected consequences or effects. Factors which could cause actual results to differ materially from current expectations include, without limitation: the failure to successfully develop or commercialize the company’s products; adverse changes in general economic conditions or applicable laws, rules and regulations; and other factors detailed from time to time in the company’s reports filed with the U.S Securities and Exchange Commission and the Canadian Securities Commissions.

Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement and are made only as of the date of this presentation. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
VBI Vaccines Overview

**HEADQUARTERS – CAMBRIDGE, MA**
- Central location in North America’s biotechnology hub
- 8 FTE, including CEO, CSO, CTO & CFO

**RESEARCH OPERATIONS – OTTAWA, CANADA**
- Exceptional R&D & product development experience across 25 FTEs
- Focused on development of VBI’s two platforms
  - **eVLP Technology**: innovative VLP platform with lead candidates in CMV & Glioblastoma
  - **Thermostable LPV**: stabilizing formulation platform including active collaborations with Sanofi & GSK

**GMP MANUFACTURING – REHOVOT, ISRAEL**
- ~50 FTE focused on manufacturing Sci-B-Vac
- GMP capable for commercial products with early stage process development capability
eVLP Platform & Rationale for Improved gB CMV Vaccine
CMV Unmet Medical Need

Cytomegalovirus (CMV) is a common virus that can cause serious, life-threatening complications in persons with weakened immune systems

PERSONS LIKELY TO DEVELOP CMV COMPLICATIONS

- **Congenital CMV:** Unborn babies whose mothers become infected with CMV during pregnancy are at high risk
  - Congenital CMV infection causes more long-term problems and childhood deaths than Down Syndrome or Fetal Alcohol Syndrome
  - In the U.S., congenital CMV causes one child to become disabled every hour
- **Immunocompromised:** A primary CMV infection can cause serious disease in organ and bone marrow transplant recipients, cancer patients, and patients receiving immunosuppressive drugs

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Jan. 2003, p. 1–7
CMV Vaccine Unmet Medical Need: Durable, broadly neutralizing antibody responses

- Naturally acquired immunity confers high protection against CMV infection (Adler\textsuperscript{7})
  - Maternal transmission rate: ~50% during primary infection but only 0.5-2% among CMV-immune women
  - CMV-immune subjects: Protected from low to moderate-dose CMV virus challenge
  - Natural immunity imparts ~90% protection

- 2009: Landmark Phase II CMV vaccine study achieved projected 50% efficacy (Pass\textsuperscript{8})
  - **Key Goal 1** - Need improved potency vs natural immunity:
    - nAb induced by previous vaccines were 10X lower than natural immunity (Cui\textsuperscript{9})
  - **Key Goal 2** - Need improved breadth of immunity:
    - Previous vaccine approaches could neutralize CMV in fibroblasts, but not epithelial cells (Cui\textsuperscript{9})
  - **Key Goal 3** - Need improved durability of immunity:
    - Efficacy appeared to wane quickly after 1st year (Lilja\textsuperscript{10})

eVLP Production – Two Genes & Cell Line Create Natural Viral Mimic
All key structural elements of enveloped viruses represented

“e” VLP Key Attributes
- Antigen presented in Virus Like Structure (common to all VLPs)
- MLV capsid protein creates viral structure (unique)
- Lipid membrane derived from production cell line (unique)
  - Multiple cell lines can be used, HEK offers ‘human’ glycosylation patterns (as virus does)
- Envelope glycoproteins presented in lipid membrane as in nature (unique)
  - May allow unique “conformation” benefits
Not All Antibodies to Envelope Glycoproteins are Equal

Multiple CMV gB Epitopes Identified with Distinct Neutralizing Properties

- **AD-1 Immuno-dominant Epitope**
  - Predominant: 38% of B cell, IgG close bind AD-1
  - Weakly neutralizing: only 2% are neutralizing

- **AD-2 Linear Epitope**
  - Infrequent but highly potent neutralization

- **AD-4 Epitope**
  - Very rare: only 5.9% of b-cell clones
  - Strongly neutralizing

- **AD-5 Epitope**
  - Very rare: only 5.9% of b-cell clones
  - Strongly neutralizing

Distinct Envelope Glycoprotein Conformations Expose Different Epitopes - Influence Potency

Pre-fusion structure of Herpes-family virus

AD-1 is buried in the pre-fusion conformation

AD-4 is more exposed

Transition is a biologic process
- Critical to virus infection (cell fusion)
- Happens in context of membrane
- ... Soluble recombinant proteins typically adopt post-fusion structures

Post-fusion structure

AD-1 more exposed
gB-G Antigen in eVLP Promotes Cell Fusion – Suggests Altered, Biologically Relevant Conformation vs Recombinant gB

Native gB Antigen

Optimized gB-G Antigen
(VSV –G protein transmembrane domain induces altered conformation that drives significant cell fusion)
Antibodies generated with gB-G eVLPs bind to gB-G but not gB-expressing eVLPs

**Samples:**
- Lane 1: VBI bivalent gB/pp65 eVLPs
- Lane 2: Paragon bivalent gB/pp65 eVLPs
- Lane 3: Paragon gB-G eVLPs (tox batch)
Cryo-EM Analysis Demonstrates Bivalent gB/pp65 eVLPs Differ Structurally From gB-G eVLPs

Structure of VLP core (with fused CMV pp65) and surface gB appear unique

Note 1) the presence of surface gB-G spikes not seen with fully native gB expression in bivalent gB/pp65 eVLPs and 2) the expected ring structure of MLV Gag core protein not seen when pp65 is fused with Gag.

Figure 1d. Selected image of Post TFF/UC Pellet Ref #153-190 at a magnification of 52,000x. Observed in the sample are: spherical particles with dense material in their interiors (red arrow) and a visible not intact second layer surrounding the dense material (green arrow, inset), proteinaceous aggregates (blue arrow). Scale Bar: 200 nm.
eVLP Presentation Improves Potency of gB Antigen

Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein.\(^1\)

**PRECLINICAL RESULTS**

- gB in eVLP generates higher levels of CMV nAbs than recombinant (gB)
- Modification of transmembrane domain further improves eVLP potency
- No adjuvant included
CMV Vaccine: Preclinical Immunology
CMV Vaccine Unmet Medical Need: Durable, broadly neutralizing antibody responses

- Naturally acquired immunity confers high protection against CMV infection (Adler\textsuperscript{7})
  - Maternal transmission rate: \(~50\%\) during primary infection but only \(0.5-2\%\) among CMV-immune women
  - CMV-immune subjects: Protected from low to moderate-dose CMV virus challenge
  - Natural immunity imparts \(~90\%\) protection

- 2009: Landmark Phase II CMV vaccine study achieved projected 50\% efficacy (Pass\textsuperscript{8})
  - **Key Goal 1** - Need improved potency vs natural immunity:
    - nAb induced by previous vaccines were 10X lower than natural immunity (Cui\textsuperscript{9})
  - **Key Goal 2** - Need improved breadth of immunity:
    - Previous vaccine approaches could neutralize CMV in fibroblasts, but not epithelial cells (Cui\textsuperscript{9})
  - **Key Goal 3** - Need improved durability of immunity:
    - Efficacy appeared to wane quickly after 1st year (Lilja\textsuperscript{10})

VBI 1501A Induces Neutralizing Antibody Titers in Rabbits Equivalent to or Exceeding Natural Infection

Key Achievement 1 & 2: Neutralization of CMV matches natural levels of immunity in Fibroblasts AND Epithelial Cells

The endpoint neutralization titer of individual rabbit sera (n=5/group) collected 28 days after a 2nd immunization are shown against CMV infection of fibroblast and epithelial cells. The neutralizing activity of CMV+ human sera were also evaluated.
Potent Durability of nAb Responses in Rabbits Vaccinated with Planned Human Doses of CMV Vaccine Candidate

Key Achievement 3: Durability of Immunity has been a barrier to past approaches
Anti-Gag Antibodies Do Not Interfere with Induction of Anti-CMV Antibodies

A

Anti-gB Anti-Gag Anti-VSV

Inverted Endpoint Titer

Grp 3 (gB-G eVLPs)
Grp 4 (gB-G eVLPs + alum)

B

Time (weeks)

Antibody Binding Titer (1x)

Naive
Gag/host cell protein-exposed

Endpoint Anti-gB Binding Titers

C

Neutralizing Activity (epithelial cells)
2 weeks after 2nd vaccination

50% Epithelial Cell nAb Titer (1x)

Cylogam®
Naive
Gag/host cell protein-exposed
Overview of VBI-1501 Purification Process

Process Optimized to Preserves Particle Integrity & Meet FDA Standards

Clarification (Depth filtration)

Concentrate particles (Tangential flow filtration)

Inactivate residual host DNA and adventitious virus (Benzonase/βPL Tx & diafiltration)

Wash and Concentrate (Diafiltration & ultracentrifugation)

Sterilize (filter)

Total particle count (~$5 \times 10^{12}$) remains constant through process

eVLP density = $9.60 \times 10^6$ particles/mL

1.15x$10^{10}$ particles/mL

1.44x$10^{12}$ particles/mL

TFF & BZ Tx

Diafiltration & UC
## Analytical Characterization of Purified and Sterilized eVLPs

<table>
<thead>
<tr>
<th>Test</th>
<th>Test Method/Assay</th>
<th>Test Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Particle Count</td>
<td>Quantitative nsTEM</td>
<td>2.93x10^{11} eVLP/mL</td>
</tr>
<tr>
<td>gB Concentration</td>
<td>Sandwich ELISA</td>
<td>29.4 µg/mL</td>
</tr>
<tr>
<td>Total Protein</td>
<td>Bradford Assay</td>
<td>415 µg/mL</td>
</tr>
<tr>
<td>Residual Host Cell DNA</td>
<td>Quantitative PCR</td>
<td>1.97 ng/mL</td>
</tr>
<tr>
<td>Residual Nucleic Acid</td>
<td>Picogreen Assay</td>
<td>240 ng/mL</td>
</tr>
<tr>
<td>Host Cell Protein</td>
<td>HEK 293 ELISA</td>
<td>436 ng/mL</td>
</tr>
<tr>
<td>Residual Benzonase</td>
<td>ELISA</td>
<td>&lt;0.25 ng/mL</td>
</tr>
<tr>
<td>Osmolality</td>
<td>Osmometric Meas.</td>
<td>275 mOsm/kg</td>
</tr>
<tr>
<td>pH</td>
<td>pH Measurement</td>
<td>7.2</td>
</tr>
<tr>
<td>Residual Betapropiolactone</td>
<td>LC-MS</td>
<td>&lt;LOD</td>
</tr>
</tbody>
</table>
Summary of eVLPs Yield & Purity

- Consistent, high yield production achieved in HEK (~200 purified doses/L)
  - Final sterile filtration step identified as focus of further process improvement (expect ~500 doses/L)

- Exceptional purity achieved for GLP toxicology and GMP clinical batches:
  - Residual host cell DNA: 0.06 ng/dose
  - Total nucleic acid: 8.1 ng/dose
  - Residual host cell protein: 14.9 ng/dose
    - ~40 total proteins present (2D gel/Mass Spec); only 1 membrane protein (CD81)

- Qualitative & quantitative release criteria established

- Robust viral clearance step confirmed (16 hrs Tx with 10mM βPL)
  - Minute Virus of Mice (MVM): 6.97 log reduction (average)
  - Murine Leukemia Virus (MLV): 6.24 log reduction (average)
CMV Phase I Clinical Trial Overview

Opportunity for Human Potency Proof of Concept with Ph I Data

**TRIAL DESIGN**

- **Target Population:** ~125 CMV-Negative Healthy Adults (18-40 yrs)
  - Grp 1: 0.5µg (gB content/dose) VBI-1501A (gB-G eVLPs+alum)
  - Grp 2: 1.0µg VBI-1501A
  - Grp 3: 2.0µg VBI-1501A
  - Grp 4: 1.0µg VBI-1501 (unadjuvanted gB-G eVLPs)
  - Grp 5: Placebo (buffer/sucrose used for VBI-1501 suspension)

- **Design:** Staggered Enrollment with Vaccinations at 0, 2, and 6 Months

- **Expected Duration:** 20 Months

- **Primary Endpoint:** Safety and Tolerability

- **Secondary Endpoints:**
  - gB binding titers – ITR
  - nAb titers in fibroblast and epithelial cells – Charles River
  - gB avidity measurement – Adler/McVoy
Acknowledgments

- **VBI Team**
  - Dave Anderson, Anne Catherine Fluckiger, Catalina Soare, Abebaw Diress, Tanvir Ahmed, Jasminka Bozic, Barthelemy Ontsouka, Isabel Yang, Diana Duque, Matt Yorke, Jonathan Hodgins, Melissa Lemieux, Misha Nossov

- **Financial Support**
  - VBI awarded $350,000 CAD grant by the National Research Council-Industrial Research Assistance Program ("NRC-IRAP")
    - NRC-IRAP supports innovative technologies developed in Canada